---
title: 'GM-CSF in Allogenic Hematopoietic Stem Cell Transplantation: from Graft-versus-Host
  Disease to Graft-versus-Tumor effect'
date: '2024-01-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38224950/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240116170636&v=2.18.0
source: heidelberg[Affiliation]
description: Allogenic hematopoietic stem-cell transplantation (allo-HSCT) is a widely
  employed treatment for a broad range of hematological malignancies because of its
  graft-versus-tumor (GvT) effect. Unfortunately, allo-HSCT is still associated with
  morbidity and mortality related to relapse and transplant complications, namely
  graft-versus-host-disease (GvHD). In an era of therapies specifically targeting
  molecular pathways, transcription factors and cytokines, a better understanding
  of ...
disable_comments: true
---
Allogenic hematopoietic stem-cell transplantation (allo-HSCT) is a widely employed treatment for a broad range of hematological malignancies because of its graft-versus-tumor (GvT) effect. Unfortunately, allo-HSCT is still associated with morbidity and mortality related to relapse and transplant complications, namely graft-versus-host-disease (GvHD). In an era of therapies specifically targeting molecular pathways, transcription factors and cytokines, a better understanding of ...